ARIPIPRAZOLE | A205064 | HETERO LABS LTD UNIT V
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
OTSUKA PHARMACEUTICAL CO., LTD. v. HETERO DRUGS LIMITED et al 3 patentsANDA 205064aripiprazole | D.N.J. | 2015-01-08 | Terminated 2017-07-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.1828
per ea
Lowest NADAC/Unit
$0.1165
per ea
Brand NDCs
0
Generic NDCs
30
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 31722083030ARIPIPRAZOLE 30 MG TABLET | $0.1828 | EA | Generic | — | 2026-10-21 |
| 60687021394ARIPIPRAZOLE 30 MG TABLET | $0.1828 | EA | Generic | — | 2026-10-21 |
| 60687021321ARIPIPRAZOLE 30 MG TABLET | $0.1828 | EA | Generic | — | 2026-10-21 |
| 16714014601ARIPIPRAZOLE 30 MG TABLET | $0.1828 | EA | Generic | — | 2026-10-21 |
| 50268009212ARIPIPRAZOLE 30 MG TABLET | $0.1828 | EA | Generic | — | 2026-10-21 |
| 60687020294ARIPIPRAZOLE 20 MG TABLET | $0.1818 | EA | Generic | — | 2026-10-21 |
Showing 6 of 30 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.